450 related articles for article (PubMed ID: 21705878)
41. [Experience with the artificial iris diaphragm in hypotonic eyes].
Keller GK; Dahlke C; Kuckelkorn R; Schrage N
Ophthalmologe; 2003 Mar; 100(3):203-8. PubMed ID: 12640549
[TBL] [Abstract][Full Text] [Related]
42. Infectious keratitis after Boston type 1 keratoprosthesis implantation.
Chan CC; Holland EJ
Cornea; 2012 Oct; 31(10):1128-34. PubMed ID: 22960647
[TBL] [Abstract][Full Text] [Related]
43. Removal of silicone oil--rewards and penalties.
Franks WA; Leaver PK
Eye (Lond); 1991; 5 ( Pt 3)():333-7. PubMed ID: 1955056
[TBL] [Abstract][Full Text] [Related]
44. Boston Type 1 Keratoprosthesis: Visual Outcomes, Device Retention, and Complications.
Goins KM; Kitzmann AS; Greiner MA; Kwon YH; Alward WL; Ledolter J; Wagoner MD
Cornea; 2016 Sep; 35(9):1165-74. PubMed ID: 27191675
[TBL] [Abstract][Full Text] [Related]
45. Silicone oil in the repair of complex retinal detachments. A prospective observational multicenter study.
Azen SP; Scott IU; Flynn HW; Lai MY; Topping TM; Benati L; Trask DK; Rogus LA
Ophthalmology; 1998 Sep; 105(9):1587-97. PubMed ID: 9754162
[TBL] [Abstract][Full Text] [Related]
46. Outcomes of Boston keratoprosthesis in aniridia: a retrospective multicenter study.
Akpek EK; Harissi-Dagher M; Petrarca R; Butrus SI; Pineda R; Aquavella JV; Dohlman CH
Am J Ophthalmol; 2007 Aug; 144(2):227-231. PubMed ID: 17543875
[TBL] [Abstract][Full Text] [Related]
47. Primary implantation of type I Boston keratoprosthesis in nonautoimmune corneal diseases.
Chang HY; Luo ZK; Chodosh J; Dohlman CH; Colby KA
Cornea; 2015 Mar; 34(3):264-70. PubMed ID: 25611395
[TBL] [Abstract][Full Text] [Related]
48. The cincinnati procedure: technique and outcomes of combined living-related conjunctival limbal allografts and keratolimbal allografts in severe ocular surface failure.
Biber JM; Skeens HM; Neff KD; Holland EJ
Cornea; 2011 Jul; 30(7):765-71. PubMed ID: 21325942
[TBL] [Abstract][Full Text] [Related]
49. Medium-term outcomes of boston type 1 keratoprosthesis implantation in Bangkok, Thailand.
Lekhanont K; Thaweesit P; Muntham D; Chuckpaiwong V; Vongthongsri A
Cornea; 2014 Dec; 33(12):1312-9. PubMed ID: 25285588
[TBL] [Abstract][Full Text] [Related]
50. Histopathology of silicone oil keratopathy in humans.
Foulks GN; Hatchell DL; Proia AD; Klintworth GK
Cornea; 1991 Jan; 10(1):29-37. PubMed ID: 2019104
[TBL] [Abstract][Full Text] [Related]
51. Boston type 1 keratoprosthesis for primary congenital glaucoma.
Haugsdal JM; Goins KM; Greiner MA; Kwon YH; Alward WL; Wagoner MD
Br J Ophthalmol; 2016 Mar; 100(3):328-31. PubMed ID: 26206789
[TBL] [Abstract][Full Text] [Related]
52. Surgical and visual outcomes of the type I Boston Keratoprosthesis for the management of aniridic fibrosis syndrome in congenital aniridia.
Bakhtiari P; Chan C; Welder JD; de la Cruz J; Holland EJ; Djalilian AR
Am J Ophthalmol; 2012 May; 153(5):967-971.e2. PubMed ID: 22265154
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of the Boston keratoprosthesis.
Ament JD; Stryjewski TP; Ciolino JB; Todani A; Chodosh J; Dohlman CH
Am J Ophthalmol; 2010 Feb; 149(2):221-228.e2. PubMed ID: 19939347
[TBL] [Abstract][Full Text] [Related]
54. Postoperative posterior segment complications in eyes treated with the Boston type I keratoprosthesis.
Goldman DR; Hubschman JP; Aldave AJ; Chiang A; Huang JS; Bourges JL; Schwartz SD
Retina; 2013 Mar; 33(3):532-41. PubMed ID: 23073339
[TBL] [Abstract][Full Text] [Related]
55. Predictors of visual outcomes following Boston type 1 keratoprosthesis implantation.
Ahmad S; Akpek EK; Gehlbach PL; Dunlap K; Ramulu PY
Am J Ophthalmol; 2015 Apr; 159(4):739-47. PubMed ID: 25555801
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of the Boston Type I Keratoprosthesis as the Primary Penetrating Corneal Procedure.
Driver TH; Aravena C; Duong HNV; Christenbury JG; Yu F; Basak SK; Aldave AJ
Cornea; 2018 Nov; 37(11):1400-1407. PubMed ID: 30157053
[TBL] [Abstract][Full Text] [Related]
57. Refractive and corneal aberrometric changes after intracorneal ring implantation in corneas with pellucid marginal degeneration.
Piñero DP; Alio JL; Morbelli H; Uceda-Montanes A; El Kady B; Coskunseven E; Pascual I
Ophthalmology; 2009 Sep; 116(9):1656-64. PubMed ID: 19643482
[TBL] [Abstract][Full Text] [Related]
58. Long-Term Results of the Boston Keratoprosthesis for Unilateral Corneal Disease.
Kosker M; Suri K; Rapuano CJ; Ayres BD; Nagra PK; Raber IM; Hammersmith KM
Cornea; 2015 Sep; 34(9):1057-62. PubMed ID: 26114818
[TBL] [Abstract][Full Text] [Related]
59. Experience with Boston keratoprosthesis type 1 in the developing world.
de Oliveira LA; Pedreira Magalhães F; Hirai FE; de Sousa LB
Can J Ophthalmol; 2014 Aug; 49(4):351-7. PubMed ID: 25103652
[TBL] [Abstract][Full Text] [Related]
60. Visual Outcomes and Complications of Type I Boston Keratoprosthesis in Children: A Retrospective Multicenter Study and Literature Review.
Fung SSM; Jabbour S; Harissi-Dagher M; Tan RRG; Hamel P; Baig K; Ali A
Ophthalmology; 2018 Feb; 125(2):153-160. PubMed ID: 28807636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
